World's Best Scientists 2026 revealed!
Award Badge
Medicine
Switzerland
2023

D-Index & Metrics

Medicine

D-Index
149
Citations
104924
World Ranking
1182
National Ranking
686

Research.com Recognitions

  • 2023 - Research.com Medicine in Switzerland Leader Award

Overview

Jeffrey A. Engelman is affiliated with the Novartis Institutes for BioMedical Research (NIBR) in the United States. Their research spans key areas within biochemistry, genetics, molecular biology, and medicine, with a focus on understanding molecular mechanisms relevant to cancer biology.

Their work is primarily concentrated in several subfields including molecular biology, oncology, pulmonary and respiratory medicine, cancer research, and pathology and forensic medicine. Within these subfields, Engelman's research addresses topics such as lung cancer treatments and mutations, cancer genomics and diagnostics, protein tyrosine phosphatases, cancer cells and metastasis, protein degradation and inhibitors, cancer mechanisms and therapy, and computational drug discovery methods.

Engelman has published multiple papers, with notable recent publications including:

  • Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms (2021) published in Cancer Cell
  • The present and future of PI3K inhibitors for cancer therapy (2021) in Nature Cancer
  • TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts (2020) in Nature Communications
  • Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling (2020) in Clinical Cancer Research
  • Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy (2023) in Cell chemical biology

Frequent co-authors collaborating with Engelman include:

  • Cyril H. Benes
  • David A. Ruddy
  • Peter S. Hammerman
  • Giordano Caponigro
  • Joel P. Wagner

Engelman's research outputs have appeared predominantly in the following publication venues:

  • UNC Libraries
  • Cancer Research
  • Nature Communications
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Cancer Research

Best Publications

  • MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Tetsuya Mitsudomi;Youngchul Song

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

    Jeffrey A. Engelman;Ji Luo;Lewis C. Cantley

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

    Jeffrey A. Engelman

  • Systematic identification of genomic markers of drug sensitivity in cancer cells

    Mathew J. Garnett;Elena J. Edelman;Sonja J. Heidorn;Christopher Greenman;Christopher Greenman

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

    Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Grit S. Herter-Sprie

  • Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

    Jeffrey A. Engelman;Jeffrey A. Engelman;Liang Chen;Xiaohong Tan;Katherine Crosby

  • Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

    Vasanthi S. Viswanathan;Matthew J. Ryan;Harshil D. Dhruv;Shubhroz Gill

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    Ryohei Katayama;Alice T. Shaw;Alice T. Shaw;Tahsin M. Khan;Tahsin M. Khan;Mari Mino-Kenudson

  • Caveolins, liquid-ordered domains, and signal transduction.

    Eric J. Smart;Gregory A. Graf;Mark A. McNiven;William C. Sessa

  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  • EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

    Jussi P. Koivunen;Craig Mermel;Kreshnik Zejnullahu;Carly Murphy

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

    Carlos L. Arteaga;Jeffrey A. Engelman

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

    Justin F. Gainor;Alice T. Shaw;Lecia V. Sequist;Xiujun Fu

Frequent Co-Authors

Alice T. Shaw
Alice T. Shaw Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University
Pasi A. Jänne
Pasi A. Jänne Harvard University
Mari Mino-Kenudson
Mari Mino-Kenudson Harvard University
Cyril H. Benes
Cyril H. Benes Harvard University
Justin F. Gainor
Justin F. Gainor Harvard University
Kwok-Kin Wong
Kwok-Kin Wong New York University
A. John Iafrate
A. John Iafrate Harvard University
Lewis C. Cantley
Lewis C. Cantley Harvard University
Jeffrey Settleman
Jeffrey Settleman Pfizer (Germany)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider studying Medicine in the USA, it’s valuable to look at related online degrees and flexible career pathways in healthcare. Many students and working professionals are drawn to accelerated healthcare programs that allow for a quicker route into administrative or clinical roles.

Registered nurses interested in leadership or advanced practice should explore adn to msn bridge programs. These programs let RNs move efficiently from an associate degree to a master’s degree, expanding their career options in less time.

If you are passionate about nutrition and preventive health, an online nutrition degree can open doors in clinical, research, or wellness fields. For working adults seeking leadership roles, finding whats the best online mha program for working adults is key to gaining advanced management skills without pausing your current career.

Each of these online pathways provides flexibility, supports work-life balance, and offers opportunities for professional growth within the rapidly evolving healthcare sector.

Best Scientists Citing Jeffrey A. Engelman

Trending Scientists

Recently Published Articles